Literature DB >> 29688155

Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma.

Robert J Lewandowski1, Ahmed Gabr1, Nadine Abouchaleh1, Rehan Ali1, Ali Al Asadi1, Ronald A Mora1, Laura Kulik1, Daniel Ganger1, Kush Desai1, Bartley Thornburg1, Samdeep Mouli1, Ryan Hickey1, Juan Carlos Caicedo1, Michael Abecassis1, Ahsun Riaz1, Riad Salem1.   

Abstract

Purpose To report long-term outcomes of radiation segmentectomy (RS) for early hepatocellular carcinoma (HCC). The authors hypothesized that outcomes are comparable to curative treatments for patients with solitary HCC less than or equal to 5 cm and preserved liver function. Materials and Methods This retrospective study included 70 patients (median age, 71 years; range, 22-96 years) with solitary HCC less than or equal to 5 cm not amenable to percutaneous ablation who underwent RS (dose of >190 Gy) between 2003 and 2016. Patients who underwent subsequent curative liver transplantation were excluded to eliminate this confounding variable affecting survival. Radiologic response of time to progression and median overall survival were estimated by using the Kaplan-Meier method per the guidelines of the European Association for the Study of the Liver (EASL) and the World Health Organization (WHO). Results Seventy patients were treated with RS over 14 years. Sixty-three patients (90%) showed response by using EASL criteria, of which 41 (59%) showed complete response. Fifty patients (71%) achieved response by using WHO criteria, of which 11 (16%) achieved complete response. Response rates at 6 months were 86% and 49% by using EASL and WHO criteria, respectively. Median time to progression was 2.4 years (95% confidence interval: 2.1, 5.7), with 72% of patients having no target lesion progression at 5 years. Median overall survival was 6.7 years (95% confidence interval: 3.1, 6.7); survival probability at 1, 3, and 5 years was 98%, 66%, and 57%, respectively. Overall survival probability at 1, 3, and 5 years was 100%, 82%, and 75%, respectively, in patients with baseline tumor size less than or equal to 3 cm (n = 45) and was significantly longer than in patients with tumors greater than 3 cm (P = .026). Conclusion RS provides response rates, tumor control, and survival outcomes comparable to curative-intent treatments for selected patients with early-stage HCC who have preserved liver function. © RSNA, 2018 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29688155     DOI: 10.1148/radiol.2018171768

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  46 in total

1.  Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Jon Bell; Carlo Chiesa; Kirk Fowers; Bonnie Hamilton; Joseph Herman; S Cheenu Kappadath; Thomas Leung; Lorraine Portelance; Daniel Sze; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-16       Impact factor: 9.236

Review 2.  Yttrium-90 Radiation Segmentectomy.

Authors:  Guy E Johnson; Siddharth A Padia
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 3.  Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention.

Authors:  Joseph H Yacoub; David Mauro; Andrew Moon; Aiwu R He; Mustafa R Bashir; Christine C Hsu; Thomas M Fishbein; Lauren M B Burke
Journal:  Abdom Radiol (NY)       Date:  2021-04-16

Review 4.  Frontiers of therapy for hepatocellular carcinoma.

Authors:  Michael Heller; Neehar D Parikh; Nicholas Fidelman; Dawn Owen
Journal:  Abdom Radiol (NY)       Date:  2021-04-10

Review 5.  Position 2: Transarterial Radioembolization Should Be the Primary Locoregional Therapy for Unresectable Hepatocellular Carcinoma.

Authors:  Syed Irfan-Ur Rahman; Laura Nunez-Herrero; Jamie Lee Berkes
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-26

Review 6.  Modified Radiation Lobectomy: An Evolving Paradigm to Convert Patients to Liver Resection Candidacy.

Authors:  Ahmed Gabr; Ahsun Riaz; Samdeep Mouli; Kush Desai; Bartley Thornburg; Riad Salem; Robert J Lewandowski
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

7.  Overview of Ablative Therapy for Hepatocellular Carcinoma.

Authors:  Steven C Rose
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-09

Review 8.  [Locoregional and local ablative treatment options for liver tumors].

Authors:  J B Hinrichs; F K Wacker
Journal:  Internist (Berl)       Date:  2020-02       Impact factor: 0.743

9.  Selective Internal Radiation Therapy for Hepatocellular Carcinoma Across the Barcelona Clinic Liver Cancer Stages.

Authors:  Carlos Moctezuma-Velazquez; Aldo J Montano-Loza; Judith Meza-Junco; Kelly Burak; Mang Ma; Vincent G Bain; Norman Kneteman; Phillipe Sarlieve; Richard J Owen
Journal:  Dig Dis Sci       Date:  2020-04-12       Impact factor: 3.199

10.  Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants.

Authors:  Ahmed Gabr; Ahsun Riaz; Guy E Johnson; Edward Kim; Siddharth Padia; Robert J Lewandowski; Riad Salem
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.